Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 15/20 | 0.38 |
| ▸ | EGFR | P00533 | 5/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TGM2 | P21980 | 1/20 | 0.34 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31745548 | 0.88 | BTK (0.38) | BTKEGFRCYP3A4CYP2D6FGFR1 | |
| SCHEMBL31745539 | 0.87 | BTK (0.40) | BTKEGFRTGM2MAP2K7 | |
| SCHEMBL31745425 | 0.85 | BTK (0.39) | BTKEGFRCYP3A4CYP2D6FGFR1 | |
| SCHEMBL31745444 | 0.78 | BTK (0.41) | BTKEGFRTGM2MAP2K7 | |
| SCHEMBL31745544 | 0.77 | FGFR4 (0.48) | BTKEGFRCYP3A4CYP2D6FGFR1 | |
| SCHEMBL31745472 | 0.75 | BTK (0.40) | BTKEGFRTGM2MAP2K7 | |
| SCHEMBL30736133 | 0.75 | FGFR4 (0.49) | BTKEGFRCYP3A4CYP2D6FGFR1 | |
| SCHEMBL25718089 | 0.74 | BTK (0.41) | BTKEGFRCYP3A4CYP2D6FGFR1 | |
| SCHEMBL31745489 | 0.73 | BTK (0.41) | BTKEGFRTGM2MAP2K7 | |
| SCHEMBL31745541 | 0.73 | CYP3A4 (0.40) | CYP3A4CYP2D6FGFR1CYP2C9FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382297-A1 | INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF | INSILICO MEDICINE IP LTD (HK) | 2025-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382297-A1 | INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF | FGFR3, FGFR2, FGFR1 | BTK 178/4885EGFR 17/4885CYP3A4 4297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.